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OBJECTIVES: To survey healthcare professional (HCP) recom-
mendations and patient practices regarding blood glucose self-
monitoring among type-2 diabetic (T2D) patients receiving
pharmacotherapy and to investigate the potential impact of a
new incretin mimetic therapy (IMT). METHODS: HCPs in the
UK (N = 50) were interviewed using structured questionnaire
methodology. The survey investigated recommended and actual
frequencies of self-monitoring according to type of therapy (oral
therapy alone [oral(s)], insulin ± oral therapy) and phase of treat-
ment (initiation, steady state), and investigated self-monitoring
recommendations for the IMT. Additionally, patients with T2D
(N = 26) were questioned by structured telephone interview.
RESULTS: The average frequency of self-monitoring recom-
mended by HCPs was 3–4 times higher for patients on insulin ±
oral than for those on oral(s) (p < 0.001). Regarding actual self-
monitoring frequencies at steady state, 50% of HCPs believed
patients on insulin ± oral tested less than recommended. Fewer
HCPs (39%) believed that patients on oral(s) self-monitored less
than recommended (p ≤ 0.05). In contrast, most patients (~70%)
believed themselves compliant, regardless of therapy type. Most
HCPs (~98%) would recommend that patients on the IMT self-
monitor less than or the same as if they were on insulin ± oral,
with the majority indicating that patients on IMT monitor less
frequently. In comparison, most HCPs (>84%) would recom-
mend that patients on IMT self–monitor the same as or more
than if they were on oral(s), with the majority indicating that
patients on IMT monitor the same as oral(s) only at steady state.
CONCLUSIONS: HCPs recommend signiﬁcantly more frequent
self-monitoring for patients on insulin ± oral than oral(s). 
HCPs perceive patients on oral(s) to be more compliant to 
self-monitoring than those on insulin ± oral. Overall, patients 
see themselves as more compliant than do HCPs. The HCP 
recommended frequency for self-monitoring with the new 
IMT would lie between the recommended frequencies for 
oral(s) and insulin ± oral, but more similar to oral(s) at steady
state.
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OBJECTIVE: Objectives were to examine prescribing patterns
of antidiabetic medications in France over time and to determine
how patient characteristics impact the likelihood of receiving
various medications. METHODS: Data were obtained from the
IMS Disease Analyzer-Mediplus France Database. Patients were
eligible if they were identiﬁed as having Type 2 diabetes during
the calendar year 2001, 2002 or 2003. Univariate analyses exam-
ined changes in patient characteristics and trends in prescribing
over time. In addition, multivariate logistic regressions were used
to analyze how prescribing patterns have changed over time.
RESULTS: A total of 14,281 unique diabetic patients were exam-
ined over the time period from 2001 to 2003. A unique drug
therapy episode was deﬁned as any use of medication or med-
ication combination for at least 45 days. Among users of antidi-
abetic agents, individuals had an average of 1.28 drug therapy
episodes per calendar year. Univariate analyses revealed that
between 2001 and 2003, monotherapy use of sulfonylurea
decreased (p < 0.0001), while monotherapy use of metformin (p
< 0.0001) and insulin (p = 0.0437) increased. Multivariate logis-
tic regressions that compared prescription therapy episodes in
2003 to those in 2001 revealed that the inﬂuence of year on like-
lihood of using metformin or insulin (either alone or in combi-
nation with other medications) was positive and signiﬁcant (p <
0.05). In contrast, the inﬂuence of year on the likelihood of using
sulfonylurea monotherapy was negative and signiﬁcant (p <
0.05). CONCLUSIONS: Antidiabetic medication prescribing
patterns have changed in France in the early 21st century. In
general, the trend has been away from sulfonylurea monother-
apy and towards metformin and insulin monotherapy or com-
bination therapy.
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Randomized controlled trials (RCT) and observational studies
with propensity score methods (PSM) are the two common
approaches to mimic counterfactual premises in estimating treat-
ment effects. Although, in theory, correct exercises of either
approach can reveal the similar truth, no empirical evidence has
shown such convergence. OBJECTIVE: To examine whether
similar studies using either approach can reach converging
results of a treatment effect. METHODS: Two small 32-week
crossover RCTs (n = 105 and 97; crossover at 16th weeks) and
one large retrospective observational study with PSM (n = 4519)
were conducted to examine and compare the marginal effect of
insulin regimen (once-daily basal analog insulin—glargine vs.
twice-daily basal and bolus analog insulin—lispro mix 75/25) on
the reduction of hemoglobin A1c (HbA1c) among patients with
type 2 diabetes. The differences in mean HbA1c reductions
between two insulin regimens were estimated as the marginal
effect for individual studies. RESULTS: Two RCTs showed that
twice-daily basal and bolus analog insulin (lispro 75/25) had 0.4
and 0.6 more units of HbA1c reduction than once-daily basal
analog insulin (glargine) respectively. Likewise, the retrospective
observational study with PSM also found that twice-daily basal
and bolus analog insulin (lispro 75/25) reduced 0.55 and 0.65
more units of HbA1c than once-daily basal analog insulin
(glargine) at the end of 1st and 2nd post-baseline quarters respec-
tively. CONCLUSIONS: Two RCTs and 1 observational study
with PSM revealed that twice-daily short-acting analog insulin
regimen (lispro 75/25) reduced more unit of HbA1c than once-
daily long-acting analog insulin regimen (glargine) did. This fact
supports that correct exercises of RCTs and observational studies
with PSM can reveal the similar level of treatment effect.
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